Please assess the completion status of the following clinical trial:

Trial Title: Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes mellitus according to the ADA criteria~* HbA1c between 6.5% and 8.5%~* Individually optimized combination therapy with metformin in combination with sulfonylurea in a stable dosage within the last 3 months~* Age between 40 and 75 years~* Fasting intact proinsulin level \> 7 pmol/Land \< 20 pmol/Lat screening~Exclusion Criteria:~* Type 1 Diabetes mellitus~* Pre-Treatment with insulin within the last 3 months prior to screening~* Pre-Treatment with PPARy-agonists (glitazones) within the last 3 months prior to screening~* Major micro- or macrovascular complications as judged by the investigator~* BMI \> 40 kg/m²~* Hypokalemia (K \< 3.5 mmol /L)~* History of drug or alcohol abuse~* Anamnestic history of hypersensitivity to the study drugs or to drugs with similar chemical structures~* History of severe or multiple allergies~* Treatment with any other investigational drug within 3 months prior to screening~* Progressive fatal disease~* History of significant cardiovascular, respiratory, gastrointestinal, hepatic (ALAT and/or ASAT \> 3 times the normal reference range), renal (creatinine \> 1.3 mg/dL in women and \> 1.7 mg/dL in men), neurological, psychiatric and/or haematological disease as judged by the investigator~* Pregnancy or breast feeding~* Sexually active women of childbearing potential not actively and consistently practicing birth control by using a medically accepted device or therapy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Insulin glargine (Type: ACTIVE_COMPARATOR): Insulin glargine, dose individually adapted to reach treatment goal (FBG \< 100 mg/dL)
- NPH Insulin (Type: ACTIVE_COMPARATOR): NPH Insulin, dose individually adapted to reach treatment goal (FBG \< 100 mg/dL)
- Insulin detemir (Type: ACTIVE_COMPARATOR): Insulin detemir, dose individually adapted to reach treatment goal (FBG \< 100 mg/dL)

Based on this trial design, predict the completion outcome and termination type (if applicable).